Trial Profile

A Randomized, Multiple-dose, Multicenter, Comparative Parallel Study To Evaluate The Efficacy, Safety And Pharmacokinetic Characteristics Of Intravenous Infusion Of Rituximab (Hetero) And Reference Medicinal Product (Rituximab, Roche) In Indian Patients Of Non-Hodgkin's Lymphoma (HERILY Study)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 02 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rituximab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisolone; Vincristine
Indications Diffuse large B cell lymphoma; Follicular lymphoma
Focus Registrational; Therapeutic Use
Acronyms HERILY
Sponsors Hetero Drugs

01 Jun 2023 Primary endpoint has been met (Overall Response rate (ORR) by International Working Group (IWG) response criteria at the end of cycle 6) , according to Cancer Chemotherapy and Pharmacology.
01 Jun 2023 Results published in the Cancer Chemotherapy and Pharmacology
05 Oct 2013 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com